23 August 2024
The Health Ministry’s Commission for the Formation of Lists of Vital and Essential Drugs and High-Care Drugs reviewed nine drugs proposed for inclusion in the Vital and Essential Drugs List.
As a result, four drugs have been approved: zanubrutinib, polatuzumab vedotin, nurulimab + prolgolimab, and a new form of daratumumab for subcutaneous administration, which has also been included in the list of cost-intensive drugs for specific conditions.
However, five drugs were not approved, and the decision on the other two was postponed until next week. This meeting was one of a series of four meetings scheduled for the end of August, during which other drugs will also be considered. The meetings are scheduled for August 23, 27 and 28.
PrintOctober 10 – World Mental Health Day
10 October 2024
Long-Term Game: NovaMedica Experts at the Pharma Marketing Conference
10 October 2024
NovaMedica in the TOP-1000 Russian Managers Rating
28 September 2024
DSM Group predicts the Russian pharmaceutical market will grow by 10% annually
18 October 2024
An extra 6.1 billion rubles will be allocated for drug provision in 2025
18 October 2024
Pharmasyntez to build heparin production plant in Tatarstan
17 October 2024
17 October 2024